Korea is repricing its medicines. It is reshuffling your go-to-market strategy.

What has been decided

On 26 March 2026, Korea's Health Insurance Policy Deliberation Committee approved the first full overhaul of drug pricing since 2012. Shin & Kim's legal summary is the clearest English account of the detail.

The base rate for generics and off-patent originators falls from 53.55% to 45% of the originator's pre-expiry price. That is a 16% cut in what the product earns, as Dailypharm calculates. The new rate took effect on 1 August for new applications, with the lower prices expected to show from October, according to the Korea JoongAng Daily. Products already listed step down in stages between 2026 and 2036.

Not every company lands at 45%. The reform prices by company profile as well as by product:

On products already on the market, certified innovative companies may hold 49% for four extra years, and quasi-innovative companies 47% for three. Entry is also harder for late arrivals: the step-down that used to start with the 20th generic of a formulation now starts with the 13th.

The savings are meant to fund the other half of the package. The ministry projects KRW 2.4 trillion a year once the cuts are fully phased in by 2036, as the Seoul Economic Daily reported. Three measures spend it:

• Flexible pricing contracts, live since June. The published list price and the price the insurer pays can now differ, with the net price agreed confidentially with the National Health Insurance Service (NHIS). The scheme covers new drugs, off-patent originators, biosimilars and incrementally modified drugs.

• A 100-day reimbursement route for rare-disease drugs. Piloted in 2026, made permanent in 2027, and extended to selected innovative drugs from 2028.

• Weighted cost-effectiveness thresholds from 2027. Disease severity, clinical benefit and budget impact will count, where one fixed ceiling used to apply.

This is a reform of reimbursed medicines. Medical devices and cosmetics are priced under separate rules and are not covered here.

1. Your Korean partner is not the company it was last year

Mid-sized Korean pharma has long been the natural home for a licensed-in European product: hospital access, a large sales force, and generic cash flow to fund both. That cash flow is what the reform cuts.

The reaction is already visible. The Korea JoongAng Daily reported in August that Ildong Pharmaceutical had declared emergency management and reset its 2026 hiring and R&D budget, that Chong Kun Dang had consolidated parts of its sales organisation, and that one mid-sized company was considering halving a KRW 120 billion plant investment. Industry sources told the paper that drugmakers with sales of KRW 20 to 30 billion had been put up for sale. A Deloitte Korea report quoted in the same article expects the market to reorganise around companies with R&D and in-house production.

We read two things into this. A differentiated product is worth more to a Korean partner than it was a year ago, because a portfolio of look-alike generics is exactly what the reform penalises. And partner diligence matters more. Before signing, ask what share of revenue comes from generics, whether the company holds innovative or quasi-innovative status, and whether the sales team in the room will still exist in twelve months.

2. If your product is off-patent, do the arithmetic before the trip

For exporters of generics, hospital injectables and value-added medicines, the numbers are tighter than the headline. A generic that misses one of the two qualification requirements (its own bioequivalence study, a registered drug substance) is capped at 36% of the originator price, and at 28.8% if it misses both, per Dailypharm.

The better rates lean towards local production. The three extra years at 60% or 50% apply where the product is made in Korea. The 68% preference for national essential medicines depends on domestically sourced raw materials. An imported product should not assume it qualifies.

There is still room in supply-critical niches. The reform widens the shortage-prevention programme, adds a policy premium of up to 10%, and exempts some of those products from volume-linked price cuts. Whether a given product fits is a question to settle line by line, with local regulatory counsel, before a distributor search starts.

3. A confidential net price changes what your contract must say

Flexible pricing removes the oldest reason to leave Korea for later: a low published price that other countries reference. Simon-Kucher notes that Korea sits in the reference basket proposed for US most-favoured-nation pricing, which raises the stakes. Uptake is real. Dailypharm reports that Roche's Polivy, UCB's Fintepla and AstraZeneca's Breztri were all listed in September with flexible agreements.

For a company without an affiliate there is a catch. The party negotiating with NHIS is whoever holds the Korean licence, which is usually your partner. The price that drives your revenue is now one that public data no longer shows. Four points belong in the agreement:

• Which price the transfer price or royalty follows: list or contracted.

• Your right to see the contracted terms.

• Who owns the registration and the reimbursement listing.

• What happens to your price if a later reassessment cuts theirs.

  
  

4. Faster listing moves the work to after launch

The 100-day route is described as reimburse first, evaluate later. Price at listing is benchmarked to foreign prices, then clinical outcomes are reviewed periodically, with possible changes to price and coverage. From 2030 a market-wide price adjustment is planned every three to five years, according to Shin & Kim.

A Korean forecast should therefore carry a price path, not a single price. And the partner has to be able to generate real-world evidence as well as sell. One multinational executive told Dailypharm the access measures were welcome but that tighter post-listing control raised questions about predictability.

5. The corridor runs both ways

The same pressure is pushing Korean companies outward. Until this year, flexible pricing was reserved for new drugs from certified innovative companies, and it served to protect a product's reference price abroad. Dailypharm cites HK inno.N's K-CAB as the one Korean drug that had it before this year. Deloitte Korea's advice to domestic firms is to cut costs while pursuing R&D and overseas expansion.

So expect more Korean companies with real products looking at Europe and South-East Asia for the revenue that generics at home no longer provide. A Korean company opening France and a French company opening Korea face the same problem in mirror image: finding the right partner, and writing the right contract.

What is still open

The generic cuts are scheduled. The access side is less settled: the weighted thresholds are not final, and the operating rules for flexible contracts are still being written, as Simon-Kucher points out. One executive quoted by the Korea JoongAng Daily expected the sales impact to show about three months after August, with harder decisions towards year-end. The Korean partner landscape will look different by spring 2027. That is a reason to map it now.

Thinking about Korea, or about expanding from Korea to Europe? Our free export diagnostic takes forty-five minutes. Write to contact@asiabiobridge.com.